195 related articles for article (PubMed ID: 30705924)
1. Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).
Ozeki M; Asada R; Saito AM; Hashimoto H; Fujimura T; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Yamada Y; Fujino A; Hirakawa S; Furukawa T; Tajiri T; Kinoshita Y; Souzaki R; Fukao T
Regen Ther; 2019 Jun; 10():84-91. PubMed ID: 30705924
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial.
Ozeki M; Endo S; Yasue S; Nozawa A; Asada R; Saito AM; Hashimoto H; Fujimura T; Yamada Y; Kuroda T; Ueno S; Watanabe S; Nosaka S; Miyasaka M; Umezawa A; Matsuoka K; Maekawa T; Hirakawa S; Furukawa T; Fumino S; Tajiri T; Takemoto J; Souzaki R; Kinoshita Y; Fujino A
Front Med (Lausanne); 2024; 11():1335469. PubMed ID: 38390569
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.
Ricci KW; Hammill AM; Mobberley-Schuman P; Nelson SC; Blatt J; Bender JLG; McCuaig CC; Synakiewicz A; Frieden IJ; Adams DM
Pediatr Blood Cancer; 2019 May; 66(5):e27614. PubMed ID: 30672136
[TBL] [Abstract][Full Text] [Related]
4. The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.
Ozeki M; Nozawa A; Yasue S; Endo S; Asada R; Hashimoto H; Fukao T
Orphanet J Rare Dis; 2019 Jun; 14(1):141. PubMed ID: 31196128
[TBL] [Abstract][Full Text] [Related]
5. Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.
Marchand A; Caille A; Gissot V; Giraudeau B; Lengelle C; Bourgoin H; Largeau B; Leducq S; Maruani A
Trials; 2022 Jul; 23(1):557. PubMed ID: 35804404
[TBL] [Abstract][Full Text] [Related]
6. Gorham-Stout disease successfully treated with sirolimus (rapamycin): a case report and review of the literature.
Liang Y; Tian R; Wang J; Shan Y; Gao H; Xie C; Li J; Xu M; Gu S
BMC Musculoskelet Disord; 2020 Aug; 21(1):577. PubMed ID: 32843029
[TBL] [Abstract][Full Text] [Related]
7. Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.
Ozeki M; Fujino A; Matsuoka K; Nosaka S; Kuroda T; Fukao T
Pediatr Blood Cancer; 2016 May; 63(5):832-8. PubMed ID: 26806875
[TBL] [Abstract][Full Text] [Related]
8. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
[TBL] [Abstract][Full Text] [Related]
9. A Case of Suspected Adverse Reactions to Sirolimus in the Treatment of Generalized Lymphatic Anomaly.
Fujii T; Shimono R; Tanaka A; Katami H
Case Rep Pediatr; 2019; 2019():3101357. PubMed ID: 31183237
[TBL] [Abstract][Full Text] [Related]
10. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
11. Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J; Baselga E; Davila V; Celis V; Diociaiuti A; El Hachem M; Mestre S; Haeberli D; Prokop A; Hanke C; Loichinger W; Quéré I; Baumgartner I; Niemeyer CM; Kapp FG
Pediatr Blood Cancer; 2021 Aug; 68(8):e28936. PubMed ID: 33580918
[TBL] [Abstract][Full Text] [Related]
12. Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights.
Ozeki M; Fukao T
Adv Wound Care (New Rochelle); 2019 Jun; 8(6):230-245. PubMed ID: 31236308
[No Abstract] [Full Text] [Related]
13. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
[TBL] [Abstract][Full Text] [Related]
14. Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy.
Cramer SL; Wei S; Merrow AC; Pressey JG
J Pediatr Hematol Oncol; 2016 Apr; 38(3):e129-32. PubMed ID: 26886375
[TBL] [Abstract][Full Text] [Related]
15. Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment.
Barnes-Saldaña F; Venegas-Andrade A; Colin-Martínez Ó; Lizardo-Rodríguez A; García-Romero MT; Durán-McKinster C
Bol Med Hosp Infant Mex; 2023; 80(3):217-221. PubMed ID: 37467447
[TBL] [Abstract][Full Text] [Related]
16. Gorham-Stout disease and generalized lymphatic anomaly--clinical, radiologic, and histologic differentiation.
Lala S; Mulliken JB; Alomari AI; Fishman SJ; Kozakewich HP; Chaudry G
Skeletal Radiol; 2013 Jul; 42(7):917-24. PubMed ID: 23371338
[TBL] [Abstract][Full Text] [Related]
17. Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations.
Triana P; Miguel M; Díaz M; Cabrera M; López Gutiérrez JC
Lymphat Res Biol; 2019 Oct; 17(5):504-511. PubMed ID: 30985248
[No Abstract] [Full Text] [Related]
18. Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus.
Dvorakova V; Rea D; O'Regan GM; Irvine AD
Pediatr Dermatol; 2018 Jul; 35(4):533-534. PubMed ID: 29582448
[TBL] [Abstract][Full Text] [Related]
19. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
Geeurickx M; Labarque V
J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
[TBL] [Abstract][Full Text] [Related]
20. A prospective multicenter study of sirolimus for complicated vascular anomalies.
Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
